TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04815421

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: the paste group
Description: Patients in the paste group were treated with Nanxing paste on the affected region include shoulder, neck or back and no more than 3 pieces. The paste lasted for 24 hours and then peeled it rested the pasted region for 24 hours and changed another paste on the pain region. The therapy duration was 6 days.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: the meridian group
Description: Patients in the meridian group were treated with dredging the same side three yang meridian techniques(include the gliding techniques of deep tissue massage on three yang meridians of back hand (the second, fourth and fifth metacarpal bone); pinching and kneading the second, fourth and fifth phalanges of fingers of the affected side hand; Encourage the patient to try his best to roll his neck to the most tolerable degree during dredging the meridian) and the total time was about 3 to 5 minutes according the tolerance of every patient . The massage will not stop until the meridian route was relatively smooth, soft and thermal or light red. The sequence of massage is Hand Yangming meridian(LI) the first, Hand Taiyang meridian(SI) the second and Hand Sanjiao(SJ) the last. The frequency of massage was once a day.
Study: NCT03660436

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986165
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MMF
Description: Specified dose on specified days
Study: NCT03359577

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Psorax35
Description: This is a randomized, 32 weeks, single center, placebo controlled, double blind study to investigate Psorax35 supplementation in patients with mild to moderate Psoriasis. Groups of patients will be block randomized using randomly selected block sizes, and stratified according to gender.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: MCT oil
Description: This is a randomized, 32 weeks, single center, placebo controlled, double blind study to investigate Psorax35 supplementation in patients with mild to moderate Psoriasis. Groups of patients will be block randomized using randomly selected block sizes, and stratified according to gender.
Study: NCT02721836

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga
Description: Yoga intervention 12 weeks, twice weekly 75-minute intervention Yoga postures, breathing, relaxation, and meditation

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nutrition Counselling
Description: Evidence-based Nutrition Counselling, 3 appointments within 12 weeks
Study: NCT02494050

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Activation-Full
Description: Behavioral Activation proposes that symptom reduction occurs via monitoring daily activities to identify patterns of low reward and mood, assessing and assigning tasks that generate pleasure and competence, understanding and reducing unproductive avoidance, and improving skill deficits to promote action towards treatment goals.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Activation-Short
Description: Behavioral Activation proposes that symptom reduction occurs via monitoring daily activities to identify patterns of low reward and mood, assessing and assigning tasks that generate pleasure and competence, understanding and reducing unproductive avoidance, and improving skill deficits to promote action towards treatment goals.
Study: NCT04149808

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mepilex Ag (burn dressing)
Description: Dressing for low to medium exuding burns and wounds.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Xeroform Dressing
Description: Standard of care dressing for low to medium exuding burns and wounds.
Study: NCT02494050

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Bipolar Disorder Collaborative Care
Description: This manualized treatment focuses on social support and educating patients about medication compliance. The primary focus is to strengthen the patients' self-management skills with education; supporting the clinician's decision making using practice guidelines; enhancing access to care, continuity of care, and information flow through the use of the clinician.
Study: NCT03313830

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey Protein Hydrolysate (WPH)
Description: Subjects will ingest WPH on one occasion.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Intact Whey Protein (WHEY)
Description: Subject will ingest WHEY on another occasion.
Study: NCT04709510

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Duplex Ultrasound
Description: Duplex Ultrasound was performed for every participants for the diagnosis of symptomatic or asymptomatic deep vein thrombosis
Study: NCT00945659

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Glucose Sensor
Description: Education and medical management to promote optimal therapeutic benefit from adding use of a continuous glucose sensor to daily diabetes management.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Intensified diabetes management based on either insulin pump or multiple daily injection insulin regimen, employing carbohydrate counting and a bolus dose correction factor for adjusting insulin doses.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CGS + Behavior Therapy
Description: Patients in this group will receive 6 scheduled encounters with a behavior therapist who will assist the adolescent and parent in reducing or eliminating common behavioral and psychological barriers to achieving optimal benefit from CGS use in diabetes care.
Study: NCT04153747

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-power and short-duration radiofrequency ablatio (70 W / 9-10 s)
Description: Pulmonary veins electrical isolation: high-power and short-duration ablation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low-power (25-40 W) radiofrequency ablation guided by lesion size index (LSI) and ablation index (AI) values
Description: Pulmonary veins electrical isolation: low-power ablation.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Esophageal endoscopy
Description: Esophageal endoscopy to detect postablation esophageal thermal lesions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Esophageal endoscopy
Description: Esophageal endoscopy to detect postablation esophageal thermal lesions.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Daily 30-seconds ECG
Description: Transtelephonic daily 30-seconds single lead electrocardiogram

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Daily 30-seconds ECG
Description: Transtelephonic daily 30-seconds single lead electrocardiogram
Study: NCT01104675

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ENMD-2076
Description: 275 mg (or 250 mg for BSA \< 1.65) per day in oral capsules in 28 day continuous cycles
Study: NCT01088659

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a [Pegasys]
Description: 180mcg sc weekly, 96 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a [Pegasys]
Description: 180mcg sc weekly, 96 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: orally daily, 96 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tenofovir
Description: 245mg po daily, 96 weeks
Study: NCT02578836

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fogel Gastroplasty
Description: The subject will be placed under general anesthesia. The procedure will last approximately 1-2 hours. CO2 will be used rather than air for the insufflation that is required during the procedure to minimize abdominal distention. The physician will place an interrupted suture pattern in a manner which partitions the greater curvature of the stomach from the Angle of His to the level of the incisura, creating a tube-like passage for gastric volume reduction. Afterwards, the remaining gastric volume will be reduced using a circumferential running stitch.The device that will be used to place the stitches is the OverStitch system FDA approved for tissue apposition
Study: NCT01842945

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behavioural therapy (iCBT) without therapist contact.
Description: The iCBT consists of our structured self-help program lasting a total of eight active treatment weeks and does not include a therapist contact.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behavioural therapy (iCBT) with therapist contact.
Description: The iCBT consists of our structured self-help program lasting a total of eight active treatment weeks and includes a therapist contact.
Study: NCT03352024

Intervention type: OTHER
Group type: OTHER
Intervention: Relational care
Description: Relational care is combined with a cutaneous anesthesia (Transcutaneous device(plan) of lidocaïne-pilocaïne (EMLA®))

Intervention type: OTHER
Group type: OTHER
Intervention: Hypno-analgesia
Description: Hypno-analgesia is combined with a cutaneous anesthesia (Transcutaneous device(plan) of lidocaïne-pilocaïne (EMLA®))
Study: NCT00424645

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voraxaze (Glucarpidase)
Description: 50 units/kg IV within 12 hours of study eligibility being confirmed.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered by IV within 12 hours of study eligibility being confirmed.
Study: NCT04290819

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Creatine Monohydrate
Description: 0.1g/kg of body weight (pre measured creatine) and 3mg/kg of body weight (pre measured micronized cellulose powder-caffeine placebo) self administered 1 hr prior to working out mixed in water.
Study: NCT03677310

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3% Sodium Chloride
Description: 3% sodium chloride will be given intravenously at a rate of 10 cc/hour over a period of 24 hours beginning immediately prior to incision.
Study: NCT04290819

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Creatine Monohydrate and Caffeine
Description: 0.1g/kg body weight (pre measured creatine) and 3mg/kg body weight (pre measured caffeine) self administered 1hr prior to working out mixed in water.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Caffeine
Description: 3mg/kg of body weight (pre measured caffeine) and 0.1g/kg of bodyweight (pre measured maltodextrin- creatine placebo) self administered 1 hr prior to working out mixed in water.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.1g/kg of body weight (pre measured maltodextrin) and 3mg/kg of body weight (pre measured micronized cellulose powder) self administered 1 hr prior to working out mixed in water.
Study: NCT01946191

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 24 months of personalized coaching through the EHR patient portal, with 24 scheduled contacts.
Description: Participants were assigned to a specific coach, who contacted the participants via the EHR weekly for 1 month, biweekly in months 2 to 6, monthly in months 7 to 12, and quarterly in months 13 to 24, for a total of 24 scheduled contacts. Coaching group participants received brief questionnaires relevant to weight management, including a text field where they could discuss questions or barriers. On the basis of participant responses and self-monitoring data in the EHR flow sheets, coaches wrote a brief personalized note with advice on questionnaire topics and responses to any queries or barriers mentioned by the participant. Coaching participants who did not complete questionnaires or log information into the flow sheet for 2 weeks were considered inactive and were contacted by telephone or e-mail and invited to reengage at any time. Coaching participants were able to send secure messages to the coach.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online self-monitoring
Description: Participants were encouraged to log in daily and enter data on weight, diet, and physical activity.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Online self-monitoring
Description: Participants were encouraged to log in daily and enter data on weight, diet, and physical activity.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Real-time updates to Primary Care physicians
Description: Referring PCPs of coaching group participants received regular support, including real-time progress reports with counseling tips delivered via the EHR, notification of weight change in increments of at least 10 pounds, and annual progress reports at 12 and 24 months.
Study: NCT04401462

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tension band wiring or plate fixation
Description: Operative fixation of olecranon fracture with either of the methods mentioned in the intervention name

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sling or a long-arm plaster
Description: Non-operative treatment and progressive range of motion as tolerated. A long-arm plaster will be used, if necessary, for pain relief.
Study: NCT03405714

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brivaracetam
Description: * Pharmaceutical form: Solution for iv injection~* Route of administration: intravenous use~* Concentration: 10 mg/ml
Study: NCT03811470

Intervention type: OTHER
Intervention: Standard diabetes management model in each MMC center
Description: Standard diabetes management model in each MMC center
Study: NCT02459015

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Implantation
Description: A peripheral nerve defect up to 26 mm in the finger will be repaired by implantation of either a Reaxon® Nerve Guide or an autologous nerve graft (depending on the randomization group) on day 0.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implantation
Description: A peripheral nerve defect up to 26 mm in the finger will be repaired by implantation of either a Reaxon® Nerve Guide or an autologous nerve graft (depending on the randomization group) on day 0.
Study: NCT03677310

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Normal Saline
Description: Normal Saline will be given intravenously at a rate of 10 cc/hour over a period of 24 hours beginning immediately prior to incision.
Study: NCT02247674

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bilateral movement training
Description: Exercise training of bilateral isometric handgrip force training group consisted of 60 minutes of bilateral isometric handgrip force training 3 days per week for 4 weeks (total 12 sessions)

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Bilateral movement training
Description: Exercise training of bilateral isometric handgrip force training group consisted of 60 minutes of bilateral isometric handgrip force training 3 days per week for 4 weeks (total 12 sessions)
Study: NCT01956266

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotional prosodic treatment
Description: The experimental treatment is consistent with the standard treatment in that it targets impairments in pitch/stress, loudness variability and control of speech rate, the core characteristics of prosodic insufficiency in PD (Darley, Aronson \& Brown, 1969). However, the experimental treatment provides an innovative and targeted emphasis on the emotional component of the disorder. The production of emotional intonation in an utterance requires varying combinations of pitch/stress, loudness, and rate. Participants will receive clinician feedback as well as auditory and visual feedback on accuracy via the VisiPitch display.
Study: NCT04151355

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin 20mg
Description: atorvastatin (20 mg once daily)
Study: NCT00981318

Intervention type: DRUG
Group type: OTHER
Intervention: lopinavir/ritonavir plus maraviroc
Description: lopinavir/ritonavir 400/100 mg bid plus maraviroc 150 mg bid
Study: NCT04315480

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: single intravenous administration 8mg/Kg
Study: NCT04121520

Intervention type: OTHER
Intervention: Questionnaire
Description: 1. Comprehensive perioperative assessment~2. Questionnaire administration
Study: NCT02344420

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Echocardiography
Description: The devices used within the study are the legally marked CRT devices from BIOTRONIK. CRT-P and CRT-D. As this is a post market study, all devices have a CE label and are used within their intended use. There are no study specific limitations nor mandatory device settings for the study.~Subjects will undergo a standard echo assessment at baseline, 6 and 12 month follow up visit in order to assess the baseline characteristics and the changes as response to resynchronization.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Minnesota Living Heart Failure Questionnaire (MLHF)
Description: MLHF will be obtained at baseline, 6 and 12 month FU. The goal of this questionnaire is to measure the subjects perception of how their heart failure and treatment affect their life. Questions are focused on physical, socio-economic, and psychological impairments that persons with congestive heart failure frequently attribute to their condition.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Six minute walk test
Description: The test will be performed at baseline, 6 and 12 month FU. The purpose of the test is to determine how far a patient can walk in six minute and relate it with the heart failure.
Study: NCT01602965

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Counseling Monthly Phone Calls
Description: the dietician will call the patient at home, and invite them to answer 11 open questions.The questionnaire collects information about weight loss, behaviors that need to be changed, problem-solving as to how to make the changes and physical activity levels.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Self Help Informative Booklet
Description: Self help informative booklet includes information on how to manage healthy weight, how to lose weight, physical activity and a simplified and abbreviated version of the main behavioural strategies
Study: NCT02939950

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bausch + Lomb Samfilcon A Soft Contact Lens
Description: soft contact lenses

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bausch + Lomb Pure Vision Soft Contact Lens
Description: soft contact lenses
Study: NCT02349971

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MR-HIFU
Description: Magnetic Resonance guided High Intensity Focused Ultrasound (MR-HIFU) provides precise and controlled delivery of focused ultrasound energy inside a lesion using an external applicator, without the need for a scalpel or needle
Study: NCT03298295

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continous Subcutaneous Insulin Infusion Catheter
Description: Catheters will be inserted into the abdomen of each patient using aseptic technique according to the following schedule: (1) 8 days before surgery, (2) 4 days before surgery and (3) 1 day before surgery (Table 1). At each time point 2 steel (Medtronic Sure-T, 9 mm) and 2 Teflon (Medtronic Quick-set®, 9 mm) CSII catheters will be inserted into the subcutaneous abdominal tissue. In total, 12 catheters will be inserted into each patient's abdomen using only the area predefined by the plastic surgeon for removal.
Study: NCT01851018

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofraction
Description: Patient reported toxicities related to Hypofraction radiation treatment (3 Gy daily, 5 fractions per week) up to a total of 36 Gy to the prostate (+/- seminal vesicles) plus brachytherapy boost (15 Gy in a single fraction) with 4 months neo-adjuvant firmagon (240 mg given as two subcutaneous injections of 120 mg at a concentration of 40 mg/mL as a starting dose with a maintenance dose of 80 mg given as one subcutaneous injection at a concentration of 20 mg/mL administered every 28 days).

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Standard
Description: Patient reported toxicities related to the Standard radiation treatment (2 Gy daily, 5 fractions per week) up to a total of 44 Gy to the prostate (+/- seminal vesicles) plus brachytherapy boost (15 Gy in a single fraction) with 4 months neo-adjuvant LHRH agonists
Study: NCT04310839

Intervention type: PROCEDURE
Intervention: Colectomy
Description: colectomy due to neoplastic (stage 1) or diverticulosis
Study: NCT01804218

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nadolol

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02072824

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin Dose Level 1
Description: Pregabalin liquid dosed daily three times a day in equally divided doses escalated to 7.0 mg/kg/day beginning at Randomization through Taper Phase then tapered to 3.5 mg/kg/day during 1 week Taper Phase

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin Dose Level 2
Description: Pregabalin liquid dosed daily three times a day in equally divided doses escalated to 14.0 mg/kg/day beginning at Randomization through Taper Phase then tapered to 3.5 mg/kg/day during 1 week Taper Phase

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Liquid dosed three times daily beginning at Randomization through Taper Phase
Study: NCT03504995

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Focal irreversible electroporation of the prostate cancer
Description: Irreversible electroporation is a non-thermal tissue ablation technique in which short duration electrical fields are used to permanently permeabilize the cell membrane.
Study: NCT00513682

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ultrase® MT20
Description: Ultrase® MT20 capsules will be administered orally with each meal during Day 1 to 15 in screening phase at a dose based on investigator's discretion. During Day 12 to 15, participants will receive high-fat diet and Ultrase® MT20 dose will be adjusted depending on symptoms of steatorrhea. This will be followed by a washout phase of 6 to 7 days, in which participants will receive only high-fat diet; then stabilized dose of Ultrase® MT20 capsule (as identified during screening phase) will be administered orally for 7 to 11 days during treatment phase. The stabilized dose should not to exceed 2500 lipase units per kilogram body weight per meal (lipase units/kg/meal).